The Board estimates that a further A$15 – 22m (US12 – 17m) will...

The Board estimates that a further A$15 – 22m (US12 – 17m) will be required to fund the
completion of the FDA clinical trial and submission for approval for sale and working capital
requirements. It is expected that this funding will be secured from international strategic​

investors and this process will commence on completion of the capital raising.

Decision for CE Mark is within 3 weeks.

Approximately 65% of EMA review questions completely resolved.
​